Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Fluvoxamine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Meiji Seika Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 02, 2013
Lead Product(s) : Fluvoxamine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Meiji Seika Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fluvoxamine
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Drug-Drug Interaction of ASN51 With Fluvoxamine, Itraconazole and Paroxetine in Healthy Subjects
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 30, 2024
Lead Product(s) : Fluvoxamine
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fluvoxamine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Recent Fluvoxamine COVID Benefits Discovered Using Cytel-Designed Platform Trial
Details : According to research study data, Fluvoxamine was found to reduce the number of COVID-19 patients ending up in hospital by approximately 30 percent.
Product Name : Luvox
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 13, 2021
Lead Product(s) : Fluvoxamine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fluvoxamine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Fluvoxamine Administration in Moderate SARS-CoV-2 (COVID-19) Infected Patients
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 22, 2021
Lead Product(s) : Fluvoxamine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fluvoxamine
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Influence of Fluvoxamine on the Pharmacokinetics of BI 409306
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 02, 2016
Lead Product(s) : Fluvoxamine
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fluvoxamine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase IV
Sponsor : Abbott Laboratories
Deal Size : Inapplicable
Deal Type : Inapplicable
Study to Evaluate Cognitive Functioning in Remitted Depression During Treatment With Fluvoxamine
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 19, 2013
Lead Product(s) : Fluvoxamine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase IV
Sponsor : Abbott Laboratories
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fluvoxamine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 16, 2013
Lead Product(s) : Fluvoxamine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable